Published in CMAJ on October 15, 1993
Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of infants in the United Kingdom. Clin Vaccine Immunol (2008) 0.85
Combined diphtheria, tetanus, pertussis, and Haemophilus influenzae type b vaccines for primary immunisation. Arch Dis Child (1996) 0.83
Population-based surveillance of Hib invasive infections in children in British Columbia Alberta and Ontario - 1995 to 1997. Can J Infect Dis (2000) 0.81
Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics (1981) 7.58
The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med (1991) 2.48
Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J (1991) 2.47
Acetaminophen prophylaxis of adverse reactions following vaccination of infants with diphtheria-pertussis-tetanus toxoids-polio vaccine. Pediatr Infect Dis J (1987) 2.20
Reflections on the efficacy of pertussis vaccines. Rev Infect Dis (1988) 2.01
Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr (1992) 1.85
Systemic Haemophilus influenzae disease: an overview. J Pediatr (1979) 1.68
Polysaccharide-protein conjugate vaccines for the prevention of Haemophilus influenzae type b disease. J Pediatr (1988) 1.30
Safety and immunogenicity of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in infancy. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J (1991) 1.15
Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr (1992) 0.99
Analyses of adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage of mouse weight gain. Pediatr Infect Dis J (1989) 0.94
Safety and immunogenicity of Haemophilus type b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants. Pediatr Infect Dis J (1991) 0.92
Comparative immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugate vaccines. Vaccine (1991) 0.88
Clinical and immunologic responses to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants injected at 3, 5, 7, and 18 months of age. J Pediatr (1991) 0.86
New vaccines against Haemophilus influenzae type b. Pediatr Clin North Am (1990) 0.79
Inactivated poliovirus vaccine: past and present experience. Vaccine (1996) 1.22
Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen- to nineteen-month-old infants. J Pediatr (1997) 1.10
Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. Am J Public Health (1998) 1.08
Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age. Pediatr Infect Dis J (1994) 1.07
Enhancing online bibliographic records to improve retrieval of reference collection monographs. Bull Med Libr Assoc (1995) 1.07
An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine (2000) 1.05
Adverse reactions to the preschool (fifth) dose of adsorbed diphtheria-pertussis-tetanus vaccine in Canadian children. CMAJ (1991) 1.04
Measles vaccination of infants in a well-vaccinated population. Pediatr Infect Dis J (1995) 0.97
Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine (2012) 0.93
A swimming pool-associated outbreak of Cryptosporidiosis in British Columbia. Can J Public Health (1994) 0.89
Ground beef consumption in noncommercial settings is a risk factor for sporadic Escherichia coli O157:H7 infection in Canada. J Infect Dis (1993) 0.89
Giardiasis outbreak from a chlorinated community water supply. Can J Public Health (1991) 0.88
Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine (2007) 0.86
Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J (2000) 0.85
Evaluation of booster doses of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in 18-month-old children. Vaccine (1995) 0.83
Local adverse reactions to adsorbed DPT vaccine--Surrey, British Columbia. Can Dis Wkly Rep (1989) 0.82
Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria. Clin Exp Immunol (1991) 0.81
Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants. Vaccine (1999) 0.81
Post-marketing surveillance of adverse events following ProHIBit vaccine--British Columbia. Can Dis Wkly Rep (1989) 0.80
Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. Pediatr Infect Dis J (1999) 0.80
Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine (1996) 0.79
Breastfeeding and antibody responses to routine vaccination in infants. Lancet (1992) 0.79
[Quality evaluation of primary health care in an urban area of southern Brazil]. Rev Saude Publica (1994) 0.78
Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old. Scand J Infect Dis (1995) 0.77
Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Dev Biol Stand (1998) 0.77
Immunogenicity of a five-component acellular pertussis vaccine in infants and young children. Arch Pediatr Adolesc Med (1994) 0.77
Host-cell reactivation of gamma-irradiated phage T1 in strains of Escherichia coli K-12. Mol Gen Genet (1969) 0.77
Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities. Arch Pediatr Adolesc Med (1994) 0.76
Controlled study of a new five-component acellular pertussis vaccine in adults and young children. J Infect Dis (1992) 0.76
Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with Haemophilus influenzae b conjugate vaccine. Vaccine (1997) 0.76
Extended follow-up of antibody levels and antigen responsiveness after 2 Haemophilus influenzae type b conjugate vaccines. J Pediatr (1999) 0.76
Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J (1995) 0.76
A Canadian multicentre case-control study of sporadic Escherichia coli 0157:H7 infection. Can J Infect Dis (1999) 0.75
Advances in children's mental health. Am Psychol (1990) 0.75
Evaluation of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) in Canadian infants. Can J Infect Dis (1994) 0.75
Reversible zidovudine-induced pure red cell aplasia. AIDS (1999) 0.75
Stability of BCG vaccine (intravesical) Theracys/BCG therapeutic ImmuCyst and its importance in clinical efficacy. Dev Biol Stand (1992) 0.75
Measles outbreak in a Vancouver school population: relative risk and vaccine efficacy. Can J Public Health (1988) 0.75
A comparative study of PENTA vaccine booster doses given at 12, 15, or 18 months of age. Vaccine (1999) 0.75
Smokeless tobacco: a northern perspective. Can Nurse (1987) 0.75
[Research on human vaccine and its trends of application]. Zhonghua Yi Xue Za Zhi (1998) 0.75
Standardization of BCG multiple puncture 40 mg and BCG live (intravesical) Theracys/BCG therapeutic Immucyst. Dev Biol Stand (1992) 0.75
The launch of an infant Haemophilus influenzae type B immunization programme in Iceland. Arctic Med Res (1991) 0.75
Interesting case: an unusual case of oral ulceration. Br J Oral Maxillofac Surg (2005) 0.75
Is Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) compatible with diphtheria-pertussis-tetanus vaccine in young infants? Pediatr Infect Dis J (1993) 0.75
Controlling air pollution: the plan to reduce nitrogen oxides (NOx) and volatile organic compounds (VOCs) emissions in Canada. Can J Public Health (1990) 0.75